Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

NCT02315326 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02315326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02315326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
December 8, 2014
Completion date
January 28, 2026
Enrollment
93 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adult patients with newly diagnosed or relapsed or refractory primary central nervous system lymphoma (pcnsl), or relapsed or refractory secondary central nervous system lymphoma (scnsl)